Once-weekly semaglutide for patients with type 2 diabetes: a cost-effectiveness analysis in the Netherlands
Objective Choosing therapies for type 2 diabetes that are both effective and cost-effective is vital as healthcare systems worldwide aim to maximize health of the population. The present analysis assessed the cost-effectiveness of once-weekly semaglutide (a novel glucagon-like peptide-1 (GLP-1) receptor agonist) versus insulin glargine U100 (the most commonly used basal insulin) and versus dulaglutide (an alternative once-weekly GLP-1 receptor agonist), from a societal perspective in the Netherlands. Research design and methods The IQVIA CORE Diabetes Model was used to project outcomes for onc... Mehr ...
Verfasser: | |
---|---|
Dokumenttyp: | Artikel |
Erscheinungsdatum: | 2019 |
Reihe/Periodikum: | BMJ Open Diabetes Research & Care ; volume 7, issue 1, page e000705 ; ISSN 2052-4897 |
Verlag/Hrsg.: |
BMJ
|
Schlagwörter: | Endocrinology / Diabetes and Metabolism |
Sprache: | Englisch |
Permalink: | https://search.fid-benelux.de/Record/base-26824682 |
Datenquelle: | BASE; Originalkatalog |
Powered By: | BASE |
Link(s) : | http://dx.doi.org/10.1136/bmjdrc-2019-000705 |